The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable
antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial
skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus
Teflaro is an antibacterial agent in a class of drugs known as cephalosporins,
which act by interfering with the bacterial cell wall.
CABP is a bacterial infection
that develops in the lungs of patients who are exposed to the bacteria in their normal environment,
and not in the hospital. ABSSSI is a bacterial infection of skin and skin structures that requires
antibiotic treatment and may require surgical treatment.
MRSA is a type of staph
bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other
more common antibiotics such as oxacillin, penicillin, and amoxicillin. In the community, most MRSA
infections are skin infections. Severe or potentially life-threatening MRSA infections occur most
frequently among patients in contact with health care settings, according to the Centers for Disease
Control and Prevention.
For more information, please visit: Teflaro